Glucagon-like peptide-1 receptor agonists, but not dipeptidyl peptidase-4 inhibitors, reduce alcohol intake
National Institutes of Health · National Institute on Drug Abuse · +15 more institutions
Abstract
BACKGROUNDDespite growing preclinical evidence that glucagon-like peptide1 receptor agonists (GLP-1RAs) could be repurposed to treat alcohol use disorder (AUD), clinical evidence is scarce. Additionally, the potential impact of dipeptidyl peptidase-4 inhibitors (DPP-4Is) on alcohol intake is largely unknown.METHODSWe conducted a large cohort study using 2008-2023 electronic health records data from the U.S. Department of Veterans Affairs. Changes in Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) scores were compared between propensity-score-matched GLP-1RA recipients, DPP-4I recipients, and unexposed comparators. We further tested the effects of 2 DPP-4Is, linagliptin and omarigliptin, on…
Citation impact
- FWCI
- 40.00
- Percentile
- 100%
- References
- 126
Authors
13- MFMehdi FarokhniaCorresponding
National Institutes of Health, National Institute on Drug Abuse, Johns Hopkins University, National Institute on Alcohol Abuse and Alcoholism
- JTJohn Tazare
London School of Hygiene & Tropical Medicine
- CPClaire Pince
National Institutes of Health, National Institute on Drug Abuse, National Institute on Alcohol Abuse and Alcoholism
- NBNicolaus Bruns
National Institutes of Health, National Institute on Drug Abuse, National Institute on Alcohol Abuse and Alcoholism
- JCJoshua C. Gray
Uniformed Services University of the Health Sciences
Topics & keywords
- Glucagon-like peptide-1
- Dipeptidyl peptidase
- Dipeptidyl peptidase-4
- Receptor
- Chemistry
- Alcohol
- Endocrinology
- Glucagon